Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome

Inclusion Criteria: * Men: age over ≥ 18 years or women: age over ≥ 18 years with finished reproductivity according to the following definition: * ≥ 12 month persistent natural (spontaneous) amenorrhoea (women aged \<50: additionally: FSH \>40MIE/ml and estrogen deficiency of \<30pg/ml or a negative estrogen test) * status post hysterectomy and / or bilateral oophorectomy * finished reproduction planning * secure diagnosis of bone marrow edema using MRT * current osteologic basic laboratory values (≤ 4 weeks before V2) according to DVO criteria * presence of an personally signed informed consent for the participation in the study Exclusion Criteria: * \- subchondral bone loss or already occurred cartilage damage due to the bone marrow edema * reactive bone marrow edema with advanced arthrotic changes in the adjacent joint (grade III and IV according to Kellgren and Lawrence) * patients with edematous changes in bone marrow due to the diagnosis of M. Sudeck / algodystrophy / Complex Regional Pain Syndrome (CRPS) * patients with known hypo- and hyperparathyroidism, osteogenesis imperfecta, osteomalacia, M. Paget or another systemic skeletal diseases, except osteoporosis * patients with bone necrosis in the painful skeletal region * patients with infectious process at the affected bone or the adjacent joint and adjacent soft parts, respectively * patients with diagnosed or assumed rheumatoid arthritis, Lupus erythematodes, collagenosis or vasculitides * patients with advanced renal insufficiency (GFR according to Cockcroft / Gault ≤ 40 ml/min/KO) * patients with malignant diseases with osseous manifestation in anamnesis/history * status post malignant basic/primary disease with large dosed chemotherapy * current or massive dose therapy completed before less than 6 weeks (\>7.5mg prednisolon equivalent) with glucocorticoids * patients with a malignant tumor disease within the past 5 years, independent from the affected organ system and independent from the implemented treatment, the presence of a relapse or metastatic invasion, except basal cell carcinoma and squamous-cell carcinoma of the skin Current treatment due to uveitis * vague/ambiguous hyper- or hypocalcemia, hyper- or hypophosphatemia * etiological vague/ambiguous AP-increase * symptomatic renal calculus or nephrocalcinosis within 2 years before V2 * recent fracture within the last 3 months independent of the localisation * non consolidated fractures * previous treatment with i.v. bisphosphonates within the last 12 months * previous treatment with oral bisphosphonates within the last 12 months and longer than 3 months * pre-treatment with prostacyclin analogs (Ilomedin® / Iloprost®) within the past 6 months * Current treatment due to inflammatory diseases of the jaw area as well as planned tooth extractions or tooth extractions less than 6 months ago or oral surgery implant treatment * pregnancy or nursing period * patients immediately involved in the conduction of the trial and relatives * patients with current proceedings related to the bone marrow edema * patients for which the participation in the study carries an increased risk under consideration of the health condition due to the assessment of the investigator * participation in another clinical trial within 30 days before study start or during the trial * participation of patient who might be dependent on the investigator, also the spouse, parents or children